Stivarga Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Regorafenib

Indications/Uses

Patients w/ metastatic colorectal cancer who have been previously treated w/ fluoropyrimidine-, oxaliplatin- & irinotecan-based chemotherapy, an anti-VEGF therapy, & if RAS wild type, an anti-EGFR therapy; w/ locally advanced, unresectable or metastatic GI stromal tumor who have been previously treated w/ imatinib mesylate & sunitinib malate; w/ hepatocellular carcinoma who have been previously treated w/ sorafenib.

Dosage/Direction for Use

160 mg (4 tab) once daily for 3 wk on therapy followed by 1 wk off therapy to comprise a cycle of 4 wk.

Administration

Should be taken with food: Take at the same time each day. Swallow whole w/ water after a light meal.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EX05 - regorafenib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Stivarga FC tab 40 mg

Packing/Price

1's

Stivarga

regorafenib

Manufacturer:

Bayer AG